Massimiliano Gilli
Azienda Ospedaliera Perugia
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Massimiliano Gilli as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:48 UTC. Open this list on ClinicalTrials.gov
- N/ANCT06458478 · Effects of the Application of a Hyper-oxygenated Gel After Oral SurgeryAzienda Ospedaliera di Perugia · unknown · Molar, Fourth, Extracting Own Teeth, Edema Face · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:48 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:48 UTC. The ranking covers the 200 most relevant of 6 PubMed records, and a shared surname and initials can bring in a namesake. All 6 on PubMed
- Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: possible role of the "hedonic" dopamine synapse.J Neurol Neurosurg Psychiatry · 198982 citationsRCR 3.5
- Analgesic action of methylphenidate on parkinsonian sensory symptoms. Mechanisms and pathophysiological implications.Arch Neurol · 198829 citationsRCR 1.5
- 16 citationsRCR 1.8
- Gemcitabine, ifosfamide and paclitaxel in advanced/metastatic non-small cell lung cancer patients: a phase II study.Cancer Chemother Pharmacol · 200813 citationsRCR 0.4
- Bornaprine vs placebo in Parkinson disease: double-blind controlled cross-over trial in 30 patients.Ital J Neurol Sci · 198610 citationsRCR 0.3
- The Italian Mauris Phase IIIb Trial of Atezolizumab Plus Carboplatin and Etoposide for Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer: 3-Year End-of-Study Results.Clin Lung Cancer · 20252 citationsRCR 0.6